Buy Sermorelin injections for Boosting Growth Hormone Levels
Sermorelin Acetate is sometimes called GRF 1-29. Sermorelin is a growth hormone releasing hormone analogue.
It is a 29-amino acid polypeptide representing the 1-29 fragment from endogenous human growth hormone releasing hormone, and is thought to be the shortest fully functional fragment of GHRH.
is used as a test for measuring growth hormone secretion. Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues.
It stimulates the pituitary gland to naturally produce increased amounts of human growth hormone. Sermorelin Acetate
is a truncated analog of a growth hormone releasing factor (GRF 1-44) that is naturally produced by the brain to stimulate pituitary production of human growth hormone.
The increased volume of Human Growth Hormone
(HGH) produced by the pituitary gland causes an increase in the production of Insulin-Like Growth Factor-1 (IGF-1) by the liver and results in the excellent benefits of this hormone peptide.
Used extensively in HRT or Human Growth Hormone Replacement Therapy, and Anti-Aging Therapy
often in conjunction with HGH injections. Purity: 99% (HPLC). 5mg per vial.
Sermorelin is a good HGH alternative.
Sermorelin Growth Hormone (GHRH) Therapy increases the volume of human growth hormone (HGH) secreted by the stimulated pituitary gland that is converted by the liver into IGF-1.
The increased amount of IGF-1 in the blood stream results an increase in metabolism and growth of new cells within the body's organs, muscles and bones.
This hormone peptide has been shown to increase lean muscle mass, reduce body fat, increase bone density, enhance the immune system, and strengthen the heart, as well as, other organs of the body.
Sermorelin Acetate is a Safe Hormone Treatment
Sermorelin is a very safe therapy. Since the increased volume of human growth hormone is produced by the body's pituitary gland, the body's endocrine system will not allow more growth hormone to be produced by the Sermorelin GH-RH stimulation of the pituitary than the body can safely process within the endocrine self-monitoring system.
Sermorelin is well tolerated by patients. Many research studies have concluded that sermorelin is a well tolerated releasing analogue of GHRH which is also suitable for use as a provocative test of growth hormone deficiency.
Sermorelin is the New HGH
Sermorelin is so effective for the delivery of human growth hormone (HGH), it is now being used together with HGH injections to improve effects. HGH itself is a hormone that is known for having effects as an anti-aging therapy with clinical studies demonstrating injectable HGH could reverse biological age in 60-80 year olds by as much as 20-years.
The Daniel Rudman study reflected improvement in health factors measured including fat to muscle ratio, skin thickness and elasticity, spinal disc density, hair growth and thickness, hand grip strength, improved libido, energy and mood.
Both Sermorelin and HGH are available by prescription and must be used by injection to be effective.
Sermorelin Acetate Boosts Natural HGH
Sermorelin, also known as GHRH, is a growth hormone-releasing hormone analogue used as a diagnostic agent. It is a 29-amino acid polypeptide representing the 1–29 fragment from endogenous human GHRH, and is thought to be the shortest fully functional fragment of GHRH. It is used as a diagnostic agent to assess growth hormone secretion. It is also used as doping agent in sports due to its correlation with increased growth of muscular and skeletal tissue. Sermorelin use is also hypothesized to improve deep rapid eye movement sleep.
Sermorelin Acetate, also known as GRF 1-29, is a Growth Hormone Releasing Hormone (GHRH) produced by the brain that stimulates the production and release of Growth Hormone (GH). Sermorelin Acetate was first developed in the 70s, which is thought to be the shortest fully functional fragment of GHRH and has been used as a test for Growth Hormone secretion. It is often used extensively in Anti-aging Therapy along with Testosterone in men. Sermorelin Acetate affects a more primary source of failure in the GH neuroendocrine axis, has more physiological activity, and its use for adult hormone deficiency is not restricted. Compared to human Growth Hormone (hGH), Sermorelin Acetate is a growth hormone secretagogue, which means that it stimulates the pituitary gland to produce and secrete growth hormone. Also, Sermorelin Acetate and Modified GRF 1-29 contains 29 amino acids whereas hGH is a larger molecule containing 191 amino acids.
Sermorelin Sales Online
Buy Sermorelin Acetate Injections Online - Buy Sermorelin Injections
Buy Sermorelin for Growth Hormone Deficiency from licensed Endocrinologists and Age Management Physicians.
Buy Human Growth Hormone Injections - Buy Growth Hormone Injections
CONTINUE TO HGH THERAPY > >
Sermorelin Medical Research
What exactly is Sermorelin?
Sermorelin is a GHRH (growth hormone–releasing hormone) peptide analogue. Its peptide sequence is comprised of 29 amino acids. This sequence is a portion of the endogenous human GHRH, and is currently considered to be the shortest synthetic peptide that possesses the full array of functional GHRH activity. Due to this fact, sermorelin is considered to be a growth hormone secretagogue.
Sermorelin has been used during research to stimulate the secretion of growth hormone from the adenohypophysis, also called the anterior pituitary gland. The anterior pituitary secretes trophic hormones. Sermorelin has also been used in research stimulation tests to assess for pituitary sufficiency in relation to the secretion of the growth hormone.
Growth hormone–releasing hormone
GHRH is 44 amino-acids polypeptide that stimulates the secretion of growth hormone from the adenohypophysis. It is also called somatocrinin or somatoliberin. It is produced in the cell bodies of periventricular arcuate neurons, and thereafter transported to the neurosecretory terminals of the neurons where they are released. The arcuate neurons do form part of the hypothalamo-hypophyseal portal system. Their release from the neurosecretory terminals occur in a pulsatile fashion and it thus follows that growth hormone (GH) release also occurs in a corresponding pulsatile fashion. GHRH binds to a secretin-type G-protein coupled serpentine receptor called the GHRH-receptor (GHRHR). Binding causes the receptor to activate both the cAMP (cyclic Adenosine Monophosphate)-dependent pathway and the phospholipase C (PLC) pathway. The terminal downstream actions of the cAMP-dependent pathway do upregulate the transcription of both the GH and GHRHR genes thereby providing a positive feedback loop that amplifies the production of GH. The GH produced is thereafter packaged in secretory vesicles. The downstream actions of the PLC pathway results in both Na+-voltage-dependent and Ca2+-dependent fusion of the secretory vesicles with the plasma membrane thereby releasing GH into the bloodstream.
The actions of GH ensure an optimal well-regulated post-natal growth. GH also promotes efficient energy metabolism. Studies have also shown that GHRH directly promotes slow wave NREM (non-rapid eye movement) sleep, and thus GHRH insufficiency causes a reduction in the amount and intensity of slow wave NREM sleep which results in either insomnia or dysomnia (sleep disorders that causes sleep to lose its restorative capacity). Studies have also shown that GHRH inhibits the actions of somatostatin. Somatostatin is a polypeptide hormone that inhibits GH secretion from the adenohypophysis. Both GHRH and somatostatin are produced in the same neuron but they are released in alternation to each other thereby resulting in the pulsatile release of GH from the neuron.
Recent research has also shown that GHRH is also produced outside the hypothalamus by pancreatic cells, gastrointestinal tract epithelial cells and in some neoplastic cells. Clinical studies have also shown that the actions of Sermorelin are similar to the GHRH actions. Thus, Sermorelin has been used to diagnose deficiencies in GH secretions. Also, Sermorelin has been investigated for its therapeutic properties as the studies discussed below show.
Sermorelin Clinical Studies
Clinical research shows that sermorelin can be used clinically to promote growth and manage GHRH deficiency.
Sermorelin and treating growth hormone (GH) deficiency. In 1999, a study entitled “Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency” was authored by Aitabh Prakash and Karen Goa and published in the journal Biodrugs. The aim of this study was to investigate whether sermorelin injection stimulates GH secretion from the adenohypophysis. The subjects of this study included adults and pre-pubertal children (both normal and those suffering from GH deficiency). The subjects were randomly divided into two groups with one group receiving intravenous sermorelin injection and the other group receiving subcutaneous sermorelin injection.
The results obtained from both groups showed that Sermorelin was able to rapidly diagnose GH insufficiency in children affected by GH deficiency.
The results also revealed that subcutaneous sermorelin injection did cause a significant increase in height in children suffering from idiopathic GH deficiency, and that this acceleration in growth rate could be maintained consistently for 36 months. Likewise, the results also revealed that both Sermorelin administrations were well tolerated with the only observable adverse effects being injection-site pain and transient facial flushing.
In summary, the findings of this study show that sermorelin stimulates GH secretion from the adenohypophysis.
Intravenous sermorelin can be used to diagnose some cases of GH deficiency, and subcutaneous sermorelin can be used to manage GH insufficiency.
Sermolelin and growth acceleration in a chronic disease state.
In 1996, Pasqualini et al conducted a study that was published under the title “Growth acceleration in children with chronic renal failure treated with growth-hormone-releasing hormone (GHRH)” in the journal Medicina. The subjects involved in this study were 9 children aged between 1 to 14 years old. They all suffered from chronic renal failure (CRF). The aim of this study was to investigate whether subcutaneous Sermorelin causes growth increase in children ailing from CRF. The subjects were categorized into 3 groups, the first group comprised of 3 children on conservative management, the second group comprised of 3 children on dialysis and the last group comprised 3 children who had undergone renal transplantation. Each of the three groups was administered with subcutaneous Sermorelin acetate (Geref ®) for a period of 3-6 months.
The results showed that the mean serum creatinine and urea levels remained stable in all the subjects except for two children on conservative management who showed an increase in their serum creatinine levels.
The results also revealed that the rate of height increase in 5 of the subjects averaged about 4.2cm/year.
In summary, the findings of this study show that sermorelin does increase the rate of growth in GH-responsive CRF children.
In conclusion, the above two studies show that Sermorelin can be used in research to diagnose cases of GH deficiency, stimulates GH secretion from the adenohypophysis, manage GH insufficiency and increase the rate of growth in GH-responsive CRF children.
The Sermorelin Acetate Peptide and HGH
Sermorelin Acetate, which shares similar structure to CJC-1295, is a bio-identical synthetic hormone that is extremely effective in increasing the amount of HGH. Human Growth Hormone is a hormone released by the body that controls the reproduction and growth of the cells and each of the organs in the body. At a young age, the body's HGH production is most active while the growth rate is at its highest point. After the age of 30, for every decade of life, there is a 14% reduction in HGH production . By the age of 40, HGH production is about 40 percent of what it was at the age of 20. With the further development of Growth Hormone Releasing Factors (GHRF), such as Modified GRF 1-29, HGH production may possibly begin again by stimulating the pituitary gland.
Sermorelin Acetate and Related Medical Research
Since 1980, scientists have been studying GHRH for many years. Dr. Daniel Rudman who pioneered the famous HGH study, was testing Sermorelin as a tool for anti-aging processes, and Dr. William Wehrenberg was looking at different peptides and particularly GHRH to identify which part of it is needed for pituitary gland stimulating response. His results after eliminating single amino acids showed that 29-acid-chains were held responsible for pituitary stimulation. Many research studies have concluded that Sermorelin is a well tolerated analogue of GHRH. As a result, this is suitable for use as a provocative test of growth hormone deficiency (Prakash and Goa 1999). In 1999, both researchers, Goa and Prakash checked Sermorelin Growth Hormone as provocative tasting method for deficiency of endogenous G-hormone. Sermorelin therapy increased the volume of hormone secreted by the stimulated pituitary gland, which is later converted by the liver into IGF-1. The increased amount of IGF-1 in the blood stream leads to many benefits from the use of Sermorelin: increasing metabolism and growth of new cells within the body’s organs and bones.